Equitable Access to 340B Act
Latest Action
Referred to the House Committee on Energy and Commerce.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Equitable Access to 340B Act (H.R. 9127) is a House bill introduced in the 118th Congress aimed at addressing issues related to the 340B Drug Pricing Program, which allows certain healthcare providers to purchase outpatient drugs at reduced prices. The bill was referred to the House Committee on Energy and Commerce but did not advance further and is currently classified as failed or expired. No official summary or full text is available to provide detailed provisions or mechanisms of the bill.
H.R. 9127 sought to modify or improve access to the 340B Drug Pricing Program but did not progress beyond committee referral and is now expired without enactment.
- The bill is titled 'Equitable Access to 340B Act' and relates to the 340B Drug Pricing Program under the health policy area.
- It was introduced in the House during the 118th Congress and referred to the House Committee on Energy and Commerce on July 24, 2024.
- The bill did not advance beyond committee referral and is currently classified as failed or expired.
Potential beneficiaries would likely include healthcare providers eligible for the 340B program, such as hospitals and clinics serving vulnerable populations, as well as patients who rely on discounted outpatient drugs. Specific beneficiaries cannot be identified due to lack of detailed bill text.
Without access to the full bill text or summary, potential concerns include unknown implementation challenges, possible costs associated with expanding or modifying the 340B program, questions about the scope of authority granted to agencies, and oversight mechanisms to ensure equitable access.
The bill was introduced in the House and referred to the Energy and Commerce Committee, which oversees health-related legislation. The 340B program has been subject to ongoing legislative and regulatory discussions regarding eligibility and program integrity. The bill's failure to advance suggests limited legislative momentum during the 118th Congress.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
If enacted, the bill could have influenced drug pricing dynamics for outpatient medications and affected healthcare providers' financial operations. Changes to the 340B program might also impact patient access to affordable medications indirectly through provider behavior or drug manufacturer pricing strategies. However, these effects cannot be confirmed without bill details.
The absence of a full bill text and official summary limits transparency and public understanding of the bill's intended changes to the 340B program. Monitoring legislative progress and ensuring availability of detailed legislative documents are essential for informed public oversight and stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.